Market revenue in 2023 | USD 4,211.1 million |
Market revenue in 2030 | USD 6,953.5 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Small molecule api |
Fastest growing segment | Small Molecule API |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule API, Small Molecule Drug Product |
Key market players worldwide | Wuxi AppTec Co Ltd, EQT Corp, Thermo Fisher Scientific Inc, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Boehringer Ingelheim, Labcorp Holdings Inc, Piramal Pharma Solutions, CordenPharma, Cambrex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator cdmo market will help companies and investors design strategic landscapes.
Small molecule api was the largest segment with a revenue share of 61.67% in 2023. Horizon Databook has segmented the Japan small molecule innovator cdmo market based on small molecule api, small molecule drug product covering the revenue growth of each sub-segment from 2018 to 2030.
Regulatory compliance, technological advancements, strong R&D capabilities, skilled workforce, strategic location, and favorable government initiatives are expected to create lucrative growth opportunities in Japan for small molecule innovator CDMOs.
The Global Health Innovative Technology (GHIT) Fund represents Japan’s inaugural Public-Private Partnership (PPP) dedicated to advancing the R&D and commercialization of novel medical solutions, such as drugs & vaccines.
It was established through collaboration between the Japanese government, private enterprises, the Bill & Melinda Gates Foundation, and international entities like the UN. The GHIT Fund leverages Japan’s expertise in drug development technology and innovation.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan small molecule innovator cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan small molecule innovator cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account